Seropositivity for anti-aquaporin-4 Abs (AQP-4-IgG) marks severe forms of optic neuritis (ON), which are part of the so-called neuromyelitis optica spectrum disorders (NMOSD), and can remain isolated or evolve into the complete phenotype of the spectrum, namely, neuromyelitis optica (NMO).
1,2 AQP-4-IgG play a pivotal diagnostic role, as they are directly involved in the pathogenetic mechanisms of NMOSD. 3 The dysregulation of the immune system that likely underlies the pathogenesis of NMOSD also accounts for the frequent association of these disorders with other organ-and non-organ specific autoimmune diseases. 2 Allogeneic bone marrow transplantation (allo-BMT) after myeloablative conditioning is a current, effective treatment for many hematologic malignancies. In post-transplant patients, neurologic complications, which include posterior reversible encephalopathy, seizures, encephalopathy, polyneuropathy and central nervous system (CNS) infections, are described, but CNS immune-mediated demyelinating diseases (IMDD), either primary 4 or secondary to chronic GvHD, 5 are rare. We report on a patient who developed AQP-4-IgG-associated ON, after allo-BMT for AML.
In 2005, a 51-year-old Caucasian woman was diagnosed with AML. In 2006, she underwent allo-BMT (the donor was the HLAmatched sister), followed by CR, without acute GvHD. Over the following years, the patient began complaining of mild and diffuse arthromyalgias, which promptly responded to low doses of corticosteroids, but that tended to recur after gradual discontinuation of therapy. In September 2013, she developed sudden bilateral visual loss until blindness in a few days. Past medical history was remarkable only for hypothyroidism secondary to post-BMT anti-TPO-seronegative Hashimoto thyroiditis (on therapy with levothyroxine, 100 μg/day). Neurological examination was unremarkable, except for visual acuity of 0/10 and for bilateral optic disc pallor. Visual evoked potentials were absent bilaterally. Visual field testing disclosed bitemporal hemianopsia. Brain magnetic resonance imaging (MRI) showed T2-weighted rare tiny nonspecific subcortical lesions, and hyperintensity and surrounding swelling in the optic chiasm, without gadolinium enhancement (Figures 1a and b) . Routine laboratory tests, including extractable nuclear antigens antibodies, angiotensinconverting enzyme, neoplastic and paraneoplastic (onconeural Abs) markers were negative or normal, except for a positive antinuclear antibodies test (titer, 1:160; granular pattern). Cerebrospinal fluid (CSF) examination disclosed 39 lymphocytes/μL, normal albumin quotient (index of blood-CSF barrier permeability). Oligoclonal IgG bands were negative. Immunophenotypic analysis of the CSF and blood cells, and, soon after, of a bone marrow biopsy excluded the recurrence of the myeloid leukemia. The donor chimerism was complete. Extensive searches on blood, serum and/or CSF for infective causes (HIV-1/2, Mycoplasma pneumoniae, Mycobacteria, HSV-1/2, Varicella Zoster Virus, CMV, EBV and Cryptococcus neoformans) performed by cultures, serology and/or real-time PCR were negative. Due to the severity of the ON, the patient's serum was then tested for AQP-4-IgG (indirect immunofluorescence on AQP-4-transfected cells; Euroimmun, Germany), which resulted positive. Spinal cord MRI, which was performed to exclude medullary lesions that can associate with AQP-4-IgG, 1,2 was normal. The patient was treated with IV 6-methylprednisolone (1 g/day for 6 days), followed by oral prednisone (100 mg/day), with slow subsequent tapering. After 3 months, her visual acuity was still 0/10 bilaterally, and she was treated with four cycles of plasma exchange, without improvement. Then, in January 2014, rituximab (562 mg/week for 4 weeks) was started to prevent new inflammatory events in the CNS. Prednisone was tapered off. On the latest follow-up (May 2014), the neurological findings were unchanged, the spinal cord MRI was normal and the brain MRI showed residual atrophy of the optic chiasm, and unchanged subcortical lesions (data not shown). Controls for the hematological disease showed persistent CR.
Our patient developed AQP-4-IgG-associated ON as a likely late complication of allo-BMT. The frequency of post-allo-BMT IMDD, which include ON, is rare, 0.5%, in the largest series of patients reported so far. 4 Six of the seven patients were transplanted from HLA-matched related donors, and the median time from transplant to the onset of neurologic symptoms was 4 months. 4 In another retrospective study on patients with severe autoimmune diseases, IMDD occurred up to 5 years after allo-BMT. 6 In our patient, the interval between allo-BMT and ON was 7 years. Allo-BMT profoundly interferes with the immune system mechanisms that regulate the balance between tolerance and immunity, and the development of autoreactive T lymphocytes in the thymus, or the emergence of autoreactive B-cell clones can be delayed throughout the long follow-up after transplantation. 7 Indeed, our patient sequentially developed Hashimoto thyroiditis, arthromyalgias, seropositivity for anti-nuclear Ab and eventually, AQP-4-IgG-seropositive ON. It is likely that these autoimmune phenomena followed a post-BMT failure of tolerance, within or without a context of chronic GvHD. Otherwise, the possibility that some pathogenic plasmablasts producing AQP-4-IgG survived the transplantation to develop ON later cannot be excluded. Regrettably, the patient's sera obtained before the allo-BMT were not available for determining AQP-4-IgG, and thus testing this hypothesis. In this regard, the fact that the donor, the patient's healthy sister, was seronegative for AQP-4-IgG is an important piece of information. Although within a different immunopathological context, Matiello et al. 8 reported an NMO patient who relapsed a few months after autologous BMT for Hodgkin lymphoma, which could be due to either T or B cells in the graft, or surviving autoreactive T or B cells within the patient. They concluded that, contrary to what is expected, BMT could even have favored the NMO relapse. 8 CSF examination was remarkable for lymphocytic pleiocytosis, which was compatible with AQP-4-IgG-associated ON. 9 Oligoclonal IgG band negativity is commonly seen in NMOSD, whereas CSF elevated total proteins or abnormal albumin quotient, which was normal in our patient, are more frequently reported. 9 In conclusion, the presence of AQP-4-IgG, and the negative findings in both CSF and bone marrow cells for recurrence of the myeloid leukemia, led to the diagnosis of AQP-4-IgG-associated ON. This is the first case in the medical literature, as the previously reported allo-BMT cases with ON or NMOSD, which included longitudinally extensive transverse myelitis, were published in the pre-AQP-4-IgG era, or no information on such Ab testing was provided. 4, 6 AQP-4-IgG positivity has prognostic meaning, as it predicts ON relapses, evolution to NMO and permanent neurological deficits.
2 Therefore, our patient, who was blind after the first attack of ON notwithstanding high-doses of corticosteroids (both IV and oral), is on rituximab, a highly efficacious drug in NMOSD. 10 Our case suggests that AQP-4-IgG-seropositive NMOSD, which needs early diagnosis and appropriate therapies, may be late autoimmune complications in post-transplant hematology patients.
Informed consents were obtained from the patient and her sister.
